Randomized trial of rivaroxaban versus warfarin in the evaluation of progression of coronary atherosclerosis - 12/12/18
Doi : 10.1016/j.ahj.2018.08.007
Juhwan Lee, MD, Rine Nakanishi, MD, PhD, Dong Li, MD, Kashif Shaikh, MD, Chandana Shekar, MD, Kazuhiro Osawa, MD, PhD, Negin Nezarat, MD, Eranthi Jayawardena, BS, Maja Blanco, MD, Matthew Chen, Matthew Sieckert, BS, Eric Nelson, BS, Darius Billingsley, BS, Sajad Hamal, MS, Matthew J. Budoff, MD ⁎ 
Los Angeles Biomedical Research Center, Harbor-UCLA Medical Center, Torrance, CA
⁎Reprint requests: Matthew J. Budoff, MD, Professor of Medicine, David Geffen School of Medicine at UCLA, Division of Cardiology, Los Angeles Biomedical Research Center, Harbor-UCLA Medical Center, 1124 W Carson St, Torrance, CA 90502.David Geffen School of Medicine at UCLA, Division of Cardiology, Los Angeles Biomedical Research Center, Harbor-UCLA Medical Center1124 W Carson StTorranceCA90502
Abstract |
Warfarin, a vitamin K antagonist, is associated with systemic vascular calcification. We evaluated whether rivaroxaban (a direct oral factor Xa inhibitor with no interaction with vitamin K) will slow the progression in coronary plaque volumes compared with warfarin in patients with nonvalvular atrial fibrillation using coronary computed tomography angiography.
Le texte complet de cet article est disponible en PDF.Plan
© 2018
Elsevier Inc. Tous droits réservés.
Vol 206
P. 127-130 - décembre 2018 Retour au numéro
Article précédent
- Long-term mortality and estimated functional capacity among women with symptoms of ischemic heart disease: From the NHLBI-sponsored Women's Ischemia Syndrome Evaluation
- Islam Y. Elgendy, Hend Mansoor, Qian Li, Yi Guo, Eileen M. Handberg, C. Noel Bairey Merz, Carl J. Pepine
- Patterns of use of targeted temperature management for acute myocardial infarction patients following out-of-hospital cardiac arrest: Insights from the National Cardiovascular Data Registry
- Christopher B. Fordyce, Anita Y. Chen, Tracy Y. Wang, Joseph Lucas, Abhinav Goyal, Graham C. Wong, Sean van Diepen, Michael C. Kontos, Timothy D. Henry, Christopher B. Granger, Matthew T. Roe
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?